Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.59 |
| ▸ | RAF1 | P04049 | 4/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | GCGR | P47871 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029325 | 0.91 | MAPK14 (0.56) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL5850170 | 0.90 | BRAF (0.56) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL5848954 | 0.84 | BRAF (0.45) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL5848416 | 0.82 | BRAF (0.49) | BRAFRAF1 | |
| SCHEMBL5848398 | 0.81 | MAPK13 (0.53) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL12856388 | 0.80 | BRAF (0.90) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL5268736 | 0.76 | CNR1 (0.58) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5849241 | 0.75 | BRAF (0.45) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL7641060 | 0.75 | BRAF (0.77) | BRAFRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL7643418 | 0.74 | BRAF (1.00) | BRAFRAF1MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6987119-B2 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-17 | — | — | US | claimed |
| US-6987119-B2 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-17 | — | — | US | disclosed |
| EP-1261602-B1 | IMIDAZOL-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-06 | — | — | EP | disclosed |
| US-20030134837-A1 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | GAIBA ALESSANDRA (GB) | 2003-07-17 | — | — | US | disclosed |
| EP-1261602-A1 | IMIDAZOL-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001066540-A1 | IMIDAZOL-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134837-A1 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885MAPK14 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.